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LORENZO DiCARLO, MD, KANU CHATTERJEE, MB, FRCP, FACC,
WILLIAM W. PARMLEY, MD, FACC, KARL SWEDBERG, MD, FACC,
BEVERLEY ATHERTON, AB, DEIRDRE CURRAN, BS, MARY CUCCI , RN
San Francisco . California
Hemodynamic effects of the new oral angiotensin-con-
vertingenzymeinhibitor, enalaprll, wereevaluatedacutely
in 15 patients with chronic heart failure and in 7 patients
after 4 weeks of maintenance therapy. Initial hemody-
namic effects were characterized by a significant increase
in cardiac index (from 2.1 ± 0.7 to 2.6 ± 0.7 liters/min
per m2) and a decrease in pulmonary capillary wedge
pressure (from 30 ± 6 to 24 ± 7 mm Hg), right atrial
pressure (from 14 ± 5 to 11 ± 4 mm Hg), mean arterial
pressure (from 96 ± 16to 80 ± 17 mm Hg) and systemic
vascular resistance (from 1,820 ± 480 to 1,200 ± 410
dynes-s-cm v) without any significant change in heart
rate , pulmonary artery pressure and pulmonary vas-
cular resistance.
During maintenance therapy, the doseof diuretic drugs
had to be increased because of systemic venous hyper-
tension. Repeat hemodynamic study showed that after
Attenuation or inhibition of the vasoconstricting effects of
angiotensin is associated with improved cardiac perform-
ance of patients with chronic heart failure (1-9). Both the
competitive antagonism of angiotensin II and its decreased
produ ction from converting enzyme inhibition can produce
this beneficial respon se ( 1-9) . The reports (3- 9) of im-
proved hemodynamic and clin ical effects of captopril, an
orally active angiotensin-converting enzyme inhibitor . have
prompted development of newer nonparenteral inhibitors
potenti ally useful for the long-term management of patient s
with chronic heart failure.
Enalapril is such a compound and is a synthetic tripeptide
analog of the known inhib itors of the naturall y occurring
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chronic therapy, cardiac index (2.1 ± 0.7 vs. 3.0 ± 0.08
liters/min per m2) and stroke volume index (24 ± 10 vs,
36 ± 7 ml/m2) remained elevated and pulmonary cap-
illary wedge pressure was lower than control (30 ± 6
vs. 16 ± 6 mm Hg), indicating sustained improvement
in left ventricular performance. Plasma renin activity
increased and plasma norepinephrine levels decreased
after enalapril therapy and these humoral changes per-
sisted during maintenance therapy.
All patients receiving chronic therapy had sympto-
matic improvement. Significant hypotension, which oc-
curred in five patients at the initiation of therapy, ap-
pears to be the major side effect. These findings suggest
that enalapril has the potential to improve the cardiac
performance of patients with chronic heart failure , and
further clinical studies are warranted.
angiotensin-converting enzyme ( 10) . As preliminary studie s
(11. 12) have reported encouraging results in lowering blood
pressure in hypertensive patients with the use of enalapril,
the potential exists for enalapril to produce beneficial effects
in patients with chron ic heart failure . The purpose of this
study . therefore . was to evaluate its hemod ynamic effects
in patient s with stable chron ic heart failure during acute and
chronic therap y. The chang es in plasma renin activity and
catecholamine levels were also determined.
Methods
Study patients. Fifteen patient s ( 12 men and 3 women)
with an age range of 24 to 82 years formed the patient
group. The duration of heart failure ranged from 6 to 120
month s. The cause of heart failure was severe ischemic heart
disease in eight patients and primary cardiomyopathy in the
other seven patients. No patient had a prior myocardial
infarction within the 3 month s preceding the study. All
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patients complained of dyspnea and fatigue and none had
angina at the time of entry into the study. Eight patients
were in New York Heart Association functional class III
and seven were in class IV before the initial hemodynamic
study. In all patients, clinical and radiologic findings of
systemic and pulmonary venous hypertension, pulmonary
artery hypertension and cardiomegaly were present. The left
ventricular ejection fraction measured by two-dimensional
echocardiography ranged from 15 to 30% in this patient
group.
Study protocol. The study was approved by the Insti-
tutional Committee on Human Research, and written in-
formed consent was obtained from each patient before the
initial hemodynamic evaluation. The use of vasodilator drugs
was discontinued 48 hours before the initial study. All pa-
tients were taking stable doses of digoxin and diuretic drugs
that were continued during the acute hemodynamic study.
The diuretic drugs were administered in the evening of each
hemodynamic evaluation. A diet restricted to 100 mEq of
sodium and 60 mEq of potassium was initiated at least 2
days before the first hemodynamic study. The patients on
long-term maintenance therapy were discharged on a "no
added salt" diet.
The hemodynamic studies were performed in the cardiac
care unit. Right atrial, pulmonary artery and pulmonary
capillary wedge pressures were measured with a balloon
flotation triple lumen catheter. Cardiac output was deter-
mined in triplicate by thermodilution technique with use of
the same catheter (13). Arterial pressure was recorded di-
rectly by radial artery cannulation. After placement of the
catheters, all patients rested in the supine position for 30
minutes and blood samples were drawn for the measure-
ments of plasma renin activity, norepinephrine levels and
serum electrolytes.
The baseline hemodynamic measurements were then per-
formed and enalapril administered. During the initial study,
hemodynamic measurements were repeated at 1, 2, 4, 6,
8, 10 and 12 hours after each administration of enalapril,
which was given orally in incremental doses of 2.5, 5 and
10 mg separated by 12 hours.
Those patients who were discharged on maintenance
therapy (10 mg twice daily) had outpatient clinical evalu-
ations every week for 4 weeks. At the end of 4 weeks, these
patients were rehospitalized for the second hemodynamic
evaluation. The hemodynamic measurements were repeated
at I, 2, 4, 6, 8, 10 and 12 hours after the last dose of
enalapril. Blood samples were again obtained for determi-
nation of plasma renin activity, norepinephrine levels and
serum electrolytes after the patients had been in the supine
position for 30 minutes.
Measurements. Plasma renin activity was measured by
the method of radioimmunoassay technique (14). Plasma
norepinephrine was measured by a radioisotope enzymatic
method (15). Derived hemodynamic indexes were calcu-
lated as follows: stroke volume index (SVI, ml/rrr') = CIJHR,
where CI is cardiac index and HR is heart rate. Stroke work
index (SWI, g-m/rrr') = SVI X (MSP - PCWP) x 0.0136,
where MSP is mean systolic pressure and PCWP is mean
pulmonary capillary wedge pressure. Systemic vascular re-
sistance (SVR, dynes's'cm- S) = (MAP - RA)/CO x 80,
where MAP is mean arterial pressure, RA is mean right
atrial pressure and CO is cardiac output. Pulmonary vascular
resistance (PVR, dynes-s-cmr ") = (MPAP - PCWP/CO
x 80), where MPAP is mean pulmonary artery pressure.
Statistical analysis. The hemodynamic data were ana-
lyzed utilizing repeated measures of variance. Changes in
plasma norepinephrine and plasma renin activity were cor-
related with hemodynamic variables utilizing paired t test.
Results
Acute hemodynamic effects. During the initial hemo-
dynamic evaluation in three patients, severe hypotension
developed (in two patients after a 2.5 mg dose and in one
patient after a 5 mg dose) and the hemodynamic response
to all three doses of enalapril was not determined. The peak
hemodynamic effects of 2.5, 5 and 10 mg of enalapril in
the remaining 12 patients, who tolerated all three doses, are
summarized in Table I. The time for the peak drug effect
was defined as the time when the maximal increase in car-
diac output occurred and after which no further significant
increase was observed based on the degree of variability
in determinations of cardiac output in the group. The max-
imal increase in cardiac output occurred approximately 2
hours after each dose. The onset and duration of action after
each dose of enalapril are illustrated in Figure 1. Effects
were observed usually at 2 hours after the oral dose and the
hemodynamic response lasted for over 12 hours.
In the group as a whole, there was a significant decrease
in mean arterial pressure, mean pulmonary wedge pressure
and systemic vascular resistance after a 2.5 mg dose; there
was a further decrease after a 5 mg dose. After a 10 mg
dose, however, there was no further change in the hemo-
dynamic variables. Cardiac index and stroke volume index
increased after a 2.5 mg dose, and the maximal increase
occurred after a 5 mg dose. No further change was observed
after increasing the dose to 10 mg. The percent change in
cardiac index, stroke volume index, mean pulmonary cap-
illary wedge pressure, systemic vascular resistance and mean
arterial pressure after 2.5, 5 and 10 mg doses is illustrated
in Figure 1. The magnitude of change after 5 and 10 mg
doses was similar.
The duration of action after each dose of enalapril is
illustrated in Figure 2. After 2 hours, cardiac index and
stroke volume index increased significantly and remained
higher than the control level during the 12 hours of obser-
vation. Similarly, mean arterial pressure, systemic vascular
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Table l. Acute Peak Hemodynamic Effects of Ena/apn l In 10 Patients
Enalapril
Dose (mg) CI SVI MAP SVR PCW HR
(control) 2. 1 :!: 0.7 24 :!: 10 96 :!: 16 1,820 :!: 480 30 :!: 6 91 :!: 18
2.5 2.4 :!: 0.7* 29 :!: 9* 90 :!: 19* 1.500 :!: 740* 26 :!: 6* 8S :!: 1St
5 2.7 :!: 0.8* 32 :!: 14* 82 :!: 12* 1.240 :!: 380* 22 :!: 9* 86 :!: 14t
10 2.6 :!: 0.8* 33 :!: 12* 80 :!: 17* 1,200 :!: 410* 24 :!: 7* 84 :!: 16t
*p < 0 05; t no srgmricant change
CI = cardiac index (liters/mm per m2) ; HR = heart rate (beats/nun). MAP = mean arterial pressure (rnrn Hg). PCW = mean pulmonary capillary
wedgepressure (rnrn Hg), SVI = stroke volume Index (co/stroke per 01 2), SVR = systermc vascular resistance (dynes-s-cm ') Mean values a standard
deviation
Figure l. Peak percent change (mean values ± standard error of
the mean) In cardiac index (e l l , stroke volume Index (SVI). mean
arter ial pressure (MAP), systemic vasc ular resistance (SVR) and
mean pulmonary capillary wedge pressure (peW p) after acute .
incrementally increas ing dose s of enalapn l in 12 patients The
magnitude of changes after the 5 and 10 mg dose. respectively,
is similar.
resistance and right atrial pressure decreased at 2 hours and
remained lower than the control level for 12 hours. There
was no significant change in heart rate, pulmonary artery
pressure or pulmonary vascular resistance. It should be noted,
however, that the control cardiac index before the 5 and
after the 10 mg dose was higher than that before the 2.5
mg dose (Fig. 2). Similarly, control mean pulmonary cap-
illary wedge pressure, mean arterial pressure and systemic
vascular resistance before the 5 and 10 mg doses were lower
than those before the 2.5 mg dose (Fig. 2). These findings
indicate continued hemodynamic effects of the previous dose,
lasting for more than 12 hours.
Long-term hemodynamic effects. The hemodynamic
effects of long-term therapy were evaluated in the seven
patients in the group whocompleted 4 weeks of maintenance
therapy. The peak hemodynamic effects of 10 mg of ena-
lapril at the initiation and after 4 weeks of maintenance
therapy are summarized in Figure 3. After chronic therapy,
a further decrease in right atrial and pulmonary capillary
wedge pressure was observed. There was a smaller but
statistically significant further decrease in systemic vascular
resistance and mean arterial pressure after chronic therapy
compared with that observed after initiation of therapy. Car-
diac index and stroke volume index were also higher after
0 2.5"'9
lZ!l5.0 "'9
-50 . '0 .0 "'9
chronic therapy. There was no change in heart rate, pul-
monary artery pressure, pulmonary vascular resistance and
stroke work index during chronic therapy.
Plasma renin activity and plasma catecholamines.
Plasma renin activity increased significantly after each dose
of enalapril during initial hemodynamic study. In seven
patients, plasma renin activity remained elevated after 4
weeks of maintenance therapy. Plasma norepinephrine lev-
els decreased during initial hemodynamic study and re-
mained lower during maintenance therapy (Fig. 4). No cor-
relation was found between initial serum sodium (Na t ) and
plasma renin activity, although in patients with lower serum
Na+ • plasma renin activity tended to be higher.
Clinical response. Five of the 15 patients developed
marked hypotension (systolic blood pressure less than 80
mm Hg) during the acute hemodynamic study, and enalapril
could not be continued in this group. Two of the fi ve became
hypotensive after 2.5 mg, one after 5 mg and two after a
10 mg dose. In four of these fi ve patients, hypotension could
be corrected by elevating the legs, and administration of
fluids or vasopressors was not required. One of these four
patients died suddenly from ventricular tachycardia 3 days
after enalapnl therapy was discontinued, This patient was
not hypotensive at the time of onset of ventricular tachy-
cardia and enalapril was not thought to be the cause of
sudden death. Another of the four patients developed renal
failure associated with hypotension during the initial hemo-
dynamic study. In this patient, after discontinuation of en-
alapril and institution of dopamine therapy, renal function
recovered. Another patient in the hypotensive group had
ischemic cardiomyopathy and was free of angina before
enalapril therapy butdeveloped recurrent episodes of angina
afterenalapril therapy was instituted and was therefore with-
drawn from enalapril treatment. Of the 10 remaining pa-
tients. I died suddenly at home 10 days after discharge on
maintenance therapy and the cause of death could not be
ascertained. Another patient discontinued enalapril therapy
by himself after 2 weeks of therapy, despite clinical im-
provement. because he did not want to continue on inves-
tigational drugs. One patient was withdrawn from the pro-
tocol because of noncompliance.
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Figure 2. Onset and duration of action in 12 patients
after 2.5,5 and 10mg of enalapril given in incremental
doses over 12 hour intervals. a, Cardiac index (CI),
stroke volume index (SVI) and mean pulmonary cap-
illary wedge pressure (PCWP). b, Mean arterial pres-
sure (MAP), systemic vascular resistance (SVR) and
heart rate. c, Mean pulmonary artery (PA) pressure,
pulmonary vascular resistance (PVR) and mean right
atrial pressure (RA). Values plotted are mean ± stan-
dard error of the mean. Significantchanges from con-
trol for all variablesoccurred within 2 hours of admin-
istration and continued through 12 hours after each
dose.
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Figure 3. Peak changes In hemody-
namic variables in seven patients after
chronicenalapril therapy. Peak effects
of 10 mg given during the acute study
and 10 mg given after I month of
chronic therapy are compared with
control values. Mean values ± stan-
dard error of the mean. Abbreviations
as in Figure 2.
3'irl: tiL 90~CI SVI 30 HR1l"'ln1",2 cc/min/"" bpm2. p< 0.05 20 p< 0.05 eo p< 0.05
DCONTROL ~IO"'9(ACUTE) • 10mg (CHRONICI
Seven patients who completed 4 weeks of maintenance
therapy experienced symptomatic improvement. The clinical
status of each of these seven patients improved by one or
two functional classes. However, in each patient, the dose
of diuretic drugs needed to be increased during this period
as all patients developed systemic venous hypertension. Thus,
the symptomatic improvement during maintenance enalapril
therapy may be related, at least partially, to the larger doses
of diuretics. These seven patients have been followed up
for 6 ± 1.5 months and have remained symptomatically
improved on the same dose of enalapril, diuretics and digitalis.
tricular function with enalapril in patients with chronic heart
failure with low cardiac output appeared at least partially
related to decreased left ventricular outflow resistance (17,18).
Arterial pressure and systemic vascular resistance decreased
in all patients and remained lower than the pretreatment
levels during maintenance therapy. Although we did not
determine changes in left ventricular volumes, it is more
than likely that the marked decrease in pulmonary capillary
wedge pressure was associated with a decreased left ven-
tricular diastolic volume. Because intraventricular pressure
(arterial pressure) also declined concurrently, it is probable
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Figure 4. Changes in plasma norepinephrine (NE) and plasma
renin activity (PRA) after acute and chronic enalapril therapy.
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Discussion
The results of the present study indicate that enalapril,
a tripeptide analog of the naturally occurring angiotensin-
converting enzyme inhibitors, produces prolonged benefi-
cial hemodynamic and clinical effects in patients with severe
chronic congestive heart failure. During initial hemody-
namic evaluation, there was a substantial increase in cardiac
output and stroke volume and a marked decrease in left
ventricular filling pressure, suggesting improved left ven-
tricular function in these patients. There was also a signif-
icant decrease in systemic venous pressure, indicating ben-
eficial effects of enalapril on right ventricular performance.
These beneficial hemodynamic effects appear to persist at
least during short -term chronic therapy. In seven patients
in whom hemodynamic evaluation was repeated after 4 weeks
of maintenance therapy, cardiac output and stroke volume
remained elevated with persistently lower right and left ven-
tricular filling pressures. Thus, in these patients, sustained
improvement in cardiac performance was observed.
Mechanism of enaIapril's beneficial effects on left ven-
tricular function. The mechanism of improved left ven-
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that the left ventricular wall stress also decreased. Thus, the
decrease of left ventricular afterload most likely was con-
tributory to improving left ventricular function with ena-
lapril. Decreased arterial pressure and unchanged or slower
heart rate, along with decreased wall stress, should also be
associated with decreased myocardial oxygen demand and
consumption, which has the potential advantage of decreas-
ing the metabolic cost, particularly in patients with chronic
ischemic heart failure. However, without direct determi-
nations of coronary hemodynamic variables, the effects of
enalapril on coronary and myocardial energetics remain
speculative.
Effect on plasma renin and norepinephrine levels.
Attenuation or inhibition of the vasoconstricting effect of
angiotensin II is the primary mechanism for the decrease of
arterial pressure and systemic vascular resistance with the
use of angiotensin-converting enzyme inhibitors (9). We
did not determine the angiotensin levels in this study, but
plasma renin activity increased and remained elevated dur-
ing enalapril therapy, which is indirect evidence that an-
giotensin II activity decreased. There was, however, a poor
correlation between the changes in systemic vascular resis-
tance and plasma renin activity, suggesting that the atten-
uation of angiotensin II activity might not be the sole mech-
anism for the reduction of arterial pressure and systemic
vascular resistance with enalapril.
There was a significant decrease in plasma norepineph-
rine levels after initiation of enalapril therapy and norepi-
nephrine levels remained lower during maintenance therapy.
Angiotensin II is known to potentiate effects of norepi-
nephrine (5,19). Thus, withdrawal of the heightened sym-
pathoadrenergic activity may have been contributory to lower
systemic vascular resistance. The changes in kinin-peptides
and prostaglandins due to inhibition of the converting en-
zyme by enalapril and their role in vasodilation remain un-
known and further studies are needed. Angiotensin II does
not appear to have a direct venoconstricting effect, but its
systemic administration is frequently associated with in-
creased right atrial and systemic pressures, which may be
related to its norepinephrine-potentiating effect (20). Thus,
the decrease of plasma norepinephrine might help to explain,
at least partially, the marked decrease in systemic and pul-
monary venous pressures that was observed in our patients
during enalapril therapy.
Comparison with captopril. It is apparent that the
hemodynamic effects of enalapril and its influence on car-
diac performance in patients with chronic heart failure are
similar to those reported with other angiotensin-converting
enzyme inhibitors such as captopril (1-9,16). This is not
surprising, because the mechanisms of vasodilation of these
agents are similar. The relative potency of these agents,
however, cannot be ascertained without determining their
effects in the same patients. It appears that enalapril has a
longer duration of action. In the present study, the hemo-
dynamic effects after a single dose of enalapril persisted for
12 hours or more.
Elevation of systemic venous pressure during chronic
therapy. In this study, during maintenance therapy, the
dose of diuretic drugs was increased because of elevation
in systemic venous pressure. No weight gain occurred de-
spite this increase. Thus, the persistence of the hemody-
namic effects of enalapril may be partly due to the increased
dose of diuretic drugs. (At the time of initiation of enalapril
therapy, there was a marked decrease in systemic venous
pressure in all patients; however, within the first 2 weeks
of maintenance therapy, systemic venous pressure increased
considerably. The mechanism of this secondary elevation
of systemic venous pressure after the initial decrease remains
unclear.) During chronic therapy, sodium intake was lib-
eralized in our patients. Before initial hemodynamic eval-
uation, sodium intake was restricted to 100 mEq/day for 48
hours. The patients receiving chronic therapy were dis-
charged on "no added salt" diets. It is likely that this
increased sodium intake caused an increase in systemic ve-
nous pressure in our patients who responded to larger doses
of diuretic drugs. However, further studies are required to
elucidate the mechanism of elevation of systemic venous
pressure observed in our patients during maintenance ena-
lapril therapy.
Clinical effects. The beneficial hemodynamic effects of
enalapril were associated with clinical improvement. All
seven patients receiving chronic therapy improved at least
by one functional class. However, clinical improvement in
this study was not evaluated objectively and further con-
trolled studies are needed to evaluate the influence of en-
alapril therapy on exercise tolerance and symptomatic im-
provement in patients with chronic heart failure.
Hypotension. As with other angiotensin-converting en-
zyme inhibitors, hypotension, particularly at the initiation
of enalapril therapy, remains the major clinical problem. In
this study, marked and persistent hypotension occurred in
5 (33%) of the 15 patients during initial hemodynamic eval-
uation and, therefore, therapy could not be continued. Hy-
potension-related complications also occurred in two pa-
tients; one developed renal failure and the other developed
episodes of rest angina. Thus, marked hypotension should
be avoided during enalapril therapy. Whether dose titration
(starting with a smaller dose) can prevent this hypotensive
response in patients with heart failure remains to be deter-
mined. However, because the present study demonstrates
that those patients who tolerate enalapril derive sustained
beneficial clinical and hemodynamic effects, further clinical
trials are warranted.
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